Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinsons Disease

ISSN： 0012-6667

Source： Drugs, Vol.59, Iss.6, 2000-06, pp. : 1233-1250

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Adenosine A2A Receptor Antagonists for Parkinsons Disease: Rationale, Therapeutic Potential and Clinical Experience

By Hauser Robert A.

Drugs & Aging, Vol. 22, Iss. 6, 2005-01 ,pp. : 471-482

Adis International

Access to resources Recommend Favorite

Catechol- O -Methyl Transferase (COMT) Inhibitors in Patients with Parkinson's Disease: Is COMT Genotype a Useful Indicator of Clinical Efficacy?

By Rinne J.O.

American Journal of PharmacoGenomics, Vol. 3, Iss. 1, 2003-01 ,pp. : 11-15

Adis International

Access to resources Recommend Favorite

Potential Therapeutic Properties of Green Tea Polyphenols in Parkinsons Disease

By Pan T. Jankovic J. Le W.

Drugs & Aging, Vol. 20, Iss. 10, 2003-01 ,pp. : 711-721

Adis International

Access to resources Recommend Favorite

Monoamine Oxidase B Inhibitors in Parkinson's Disease

CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 16, Iss. 4, 2017-07 ,pp. : 425-439

Bentham Science Publishers

Access to resources Recommend Favorite

Selective cyclooxygenase-2 inhibitors: pharmacology, clinical effects and therapeutic potential

By Ryn J.v. Pairet M.

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 5, 1997-05 ,pp. : 609-614

Informa Healthcare

Access to resources Recommend Favorite